• About us
• Contact

Advertisement

Person › Details

Matthew (Matt) Kapusta (Uniqure N.V. (Nasdaq: QURE))

Kapusta, Matthew (Matt) (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew)

 

	Organisation	Uniqure N.V. (Nasdaq: QURE)
	Group	Uniqure (Group)
	Product	Glybera®
	Product 2	Hemgenix®

Record changed: 2023-05-18

Advertisement

More documents for Matthew (Matt) Kapusta

• [1] Uniqure N.V.. (5/15/23). "Press Release: Uniqure Announces Sale of Royalty Interest in Hemgenix for up to $400 Million". Lexington, MA & Amsterdam....
• [2] Uniqure N.V.. (11/22/22). "Press Release: Uniqure Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B". Research Triangle Park, NC....
• [3] Uniqure N.V.. (6/22/21). "Press Release: Uniqure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)". Lexington, MA, Amsterdam & Paris....
• [4] Uniqure N.V.. (12/21/20). "Press Release: uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program". Lexington, MA & Amsterdam....
• [5] Uniqure N.V.. (6/24/20). "Press Release: Uniqure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy". Lexington, MA & Amsterdam....
• [6] Uniqure N.V.. (6/17/20). "Press Release: Uniqure Announces the Appointment of Leonard E. Post, Ph.D. to Its Board of Directors". Lexington, MA & Amsterdam....
• [7] Uniqure N.V.. (3/2/20). "Press Release: Uniqure Announces 2019 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....
• [8] Uniqure N.V.. (10/28/19). "Press Release: Uniqure Announces Third Quarter 2019 Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....
• [9] Uniqure N.V.. (9/27/19). "Press Release: Uniqure to Participate in Multiple Upcoming Industry Conferences in October". Lexington, MA & Amsterdam....
• [10] Uniqure N.V.. (9/3/19). "Press Release: Uniqure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B". Lexington, MA & Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.